Catch up on coverage from the second day of the 2024 Elevate-Derm West Conference in Scottsdale, Arizona.

From diet recommendations to biologic advancements, Jennifer Hsiao, MD, covered essential updates for treating patients with HS.

In a session at Elevate-Derm West, Cheever presented on the utilization of AI within dermatology to optimize patient communication and diversify research.

Expert tips from Whitney High, MD, at Elevate-Derm West 2024 guide experienced advanced practice providers in mastering dermatopathology and avoiding diagnostic pitfalls.

APPs found that patients on systemic therapies for AD experience fewer issues with adherence compared to those using topicals only.

A poster presented at the 2024 Elevate-Derm West Conference outlines the pharmacokinetic profiles of spesolimab via intravenous and subcutaneous administration.

Catch up on coverage from the first day of the 2024 Elevate-Derm West Conference in Scottsdale, Arizona.

Mark Gimbel, MD, and Whitney High, MD, presented complex cases that underscore the critical need for comprehensive approaches in diagnosing melanocytic lesions.

Roflumilast foam 0.3% significantly improved psoriasis severity, symptoms, and quality of life in patients with moderate to severe scalp and body psoriasis.

Apremilast led to a 75% improvement in PPPASI-75 in a significant portion of patients by week 16, with these improvements maintained through week 52.

Cheever shared with Dermatology Times her excitement for educational opportunities, networking, and presentations from experts in the specialty.

Share with us the topics you want to learn more about at Elevate-Derm West.

The conference aimed at providing dermatology NPs and PAs with the latest in the specialty begins today in Scottsdale, Arizona.

These findings can help clinicians better treat the psychosocial factors associated with the disease.

We want to know: Will you be attending the conference in Scottsdale later this week?

The LIBERTY-AD PED-OLE study showed clinical remission for moderate to severe atopic dermatitis.

Christopher Bunick, MD, PhD, highlights rademikibart's next-generation efficacy, showing stronger IL-4Rα binding affinity in atopic dermatitis and asthma.

Dermatology Times asked our readers to share what conferences they are looking forward to in the fourth quarter of 2024.

Catch up on coverage from the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

At Fall Clinical 2024, Christopher Bunick, MD, PhD, presented findings on the prevalence of systemic corticosteroid use among patients with atopic dermatitis and highlighted how those treated with upadacitinib achieved and sustained optimal skin clearance and itch relief long-term.